Literature DB >> 8303685

Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads.

V Pengo1, A Biasiolo.   

Abstract

We describe a novel method for the purification of aPL, in which pure CL is immobilized on octyl-sepharose beads by hydrophobic interaction. No lipid contamination was present in eluates, and the system could be reutilized three times without loosing extracting capacity. Four patients with antiphospholipid syndrome were studied. A marked decrease in aCL and LA activities was found in all patient plasmas after the passage through a CL-octyl-sepharose column. Both activities were recovered in eluates which contained beta 2-GP-I and IgGs. beta 2-GP-I was also present in normal plasma eluates, which showed no aCL and slight LA activity. This method represents an improvement in the purification of aPL, and could be useful in explaining the mechanism of action of antibodies that are obtained using pure phospholipid as extracting matrix.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8303685     DOI: 10.1016/0049-3848(93)90242-g

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

2.  Anticardiolipin in porphyromonas gingivalis antisera causes fetal loss in mice.

Authors:  H A Schenkein; J L Bradley; D B Purkall
Journal:  J Dent Res       Date:  2013-07-15       Impact factor: 6.116

3.  Anti-cardiolipin from periodontitis patients induces MCP-1 production by human umbilical vein endothelial cells.

Authors:  Harvey A Schenkein; Robert Sabatini; Thomas E Koertge; Carol N Brooks; Donald B Purkall
Journal:  J Clin Periodontol       Date:  2013-01-02       Impact factor: 8.728

4.  Anticardiolipin (aCL) in sera from periodontitis subjects activate Toll-like receptor 4 (TLR4).

Authors:  Harvey A Schenkein; Ravindar R Thomas
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.